Extreme values of hemoglobin A1c are associated with increased risks of chronic obstructive pulmonary disease in patients with type 2 diabetes: A competing risk analysis in national cohort of Taiwan diabetes study

Medicine (United States)

Volumn 94, Issue 1, 2015, Pages e367-

  Li, Chia Ing ^a,b   Li, Tsai Chung ^c,d   Liu, Chiu Shong ^a,b,e   Lin, Wen Yuan ^b,e   Chen, Ching Chu ^a,c   Yang, Sing Yu ^c   Lin, Cheng Chieh ^a,b,e  

^a China Medical University Hospital   (China)

^b Institute of Neuroscience   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d ASIA UNIVERSITY   (Japan)

^e Department of Family Medicine ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CASE MANAGEMENT; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TAIWAN; AGED; BLOOD; COMPLICATION; METABOLISM; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TAIWAN;

EID: 84921423371     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000367     Document Type: Article

References (43)

1. Chang C, Lu F, Yang YC, et al. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Res Clin Pract. 2000;50:S49-S59.
2. Janus ED, Watt NM, Lam KS, et al. The prevalence of diabetes, association with cardiovascular risk factors, and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community-based population study in Hong Kong Chinese. Hong Kong Cardiovascular Risk Factor Steering Committee. American Diabetes Association. Diabet Med. 2000;17:741-745.
3. Gu D, Reynolds K, Duan X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia. 2003;46:1190-1198.
4. Wong KC, Wang Z. Prevalence of type 2 diabetes mellitus of Chinese populations in mainland China, Hong Kong, and Taiwan. Diabetes Res Clin Pract. 2006;73:126-134.
5. Ministry of Health and Welfare, ROC. Health Statistics in Taiwan. 2010. http://www.mohw.gov.tw/EN/Ministry/Statistic.aspx?-f-list-no=474. Accessed July 18, 2014.
6. Rahbar S. The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann N Y Acad Sci. 2005;1043:9-19.
7. Krishnamurti U, Steffes MW. Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem. 2001;47:1157-1165.
8. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413-420.
9. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18:440-447.
10. Goldman MD. Lung dysfunction in diabetes. Diabetes Care. 2003;26:1915-1918.
11. Schuyler M, Niewoehner D, Inkley S, et al. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev Respir Dis. 1976;113:37-41.
12. Sandler M, Bunn A, Stewart R. Cross-section study of pulmonary function in patients with insulin-dependent diabetes mellitus. Am Rev Respir Dis. 1987;135:223-228.
13. Davis T, Knuiman M, Kendall P, et al. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract. 2000;50:153-159.
14. Liu CY, Hung YT, Chuang YL, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag. 2006;4:1-22.
15. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
16. Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008;168:1699-1704.
17. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
18. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
19. Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55:636-643.
20. ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J, et al. . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
21. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
22. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med. 2006;119 (10 suppl 1):38-45.
23. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet. 2003;362:1053-1061.
24. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2001;34:50s-59s
25. Ford E. Body mass index, diabetes, and C-reactive protein among U.S. Adults. Diabetes Care. 1999;22:1971-1977.
26. Rodriguez M, Guerrero R. Increased levels of C-reactive protein in non-controlled type 2 diabetic subjects. J Diabetes Complications. 1999;13:211-215.
27. Tan K, Chow W, Tam S, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002;87:563-568.
28. Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. Respir Med. 2002;96 (suppl A):S9-S15.
29. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136:1039-1046.
30. Callahan L, Supinski G, Augusta G. Diabetes markedly reduces respiratory pump capacity. Proc Am Thorac Soc. 2006;3:A259.
31. Kabitz HJ, Sonntag F, Walker D, et al. Diabetic polyneuropathy is associated with respiratory muscle impairment in type 2 diabetes. Diabetologia. 2008;51:191-197.
32. Kasahara Y, Tuder RM, Cool CD, et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163:737-744.
33. Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest. 2004;125:626-632.
34. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336-30343.
35. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest. 1995;95:1798-1807.
36. Kanazawa H, Asai K, Hirata K, et al. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med. 2003;114:354-358.
37. Xiao X, Guo P, Chen Z, et al. Hypoglycemia reduces vascular endothelial growth factor A production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636-8646.
38. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes Metab Res Rev. 2008;24:353-363.
39. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003;114:758-762.
40. Alessandri C, Basili S, Violi F, et al. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost. 1994;72:343-346.
41. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1008-1011.
42. Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106:2555-2560.
43. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995-2004.